

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On October 1, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Patricia Andree

PATENT
Attorney Docket No.: 015280-259120US
Client Ref. No.: E-002-96/2

RECEIVED
OCT 12 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PASTAN *et al.*

Application No.: 09/684,599

Filed: October 5, 2000

For: MESOTHELIN, A
DIFFERENTIATION ANTIGEN
PRESENT ON MESOTHELIUM,
MESOTHELIOMAS AND OVARIAN
CANCERS AND METHODS AND KITS
FOR TARGETING THE ANTIGEN

Examiner: Holleran, Anne

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

816
160
101301


Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants respond herein to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed August 30, 2001.

In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/215,035 as the computer-readable form for the instant application. Applicants hereby state that the computer-readable form in the instant application is identical with the Sequence Listing filed in Application No. 09/215,035,

OCT 0 5 2001



RECEIVED
OCT 1 2 2001
TECH CENTER 1600/2900

PASTAN *et al.*
Application No.: 09/684,599
Page 2

PATENT

filed December 17, 1998. The information in the paper copy of the Sequence Listing enclosed herewith is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification as follows.

In the Specification:

Please replace the paragraph beginning at page 8, line 2 with the following:

B¹

Figure 1: Nucleotide sequence (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of the CAK1-9 cDNA. The nucleotide sequence (upper line) and the deduced amino acid sequence (lower line) of the CAK1 cDNA is listed with nucleotide numbers at left. The translation of CAK1 starts at nucleotides 100-102 (ATG) and terminates at 1986-88 (TGA). The putative signal peptide is underlined and a typical hydrophobic sequence for GPI anchorage is double-underlined. A likely furin cleavage site RPRFRR is underlined and the cleavage site shown by an arrow. There are four potential N-linked glycosylation sites (in bold letters). A variant polyadenylation signal (AGTAAA) is present 22 base pairs upstream from the polyadenylation tail. The original p6-1 cDNA sequence spans nucleotides 721 to 2138.--

Please replace the paragraph beginning at page 8, line 21 with the following:

B²

This invention relates to the discovery of an antigen, referred to herein as mesothelin, found on mesothelium, mesotheliomas, ovarian cancer cells and some squamous cell carcinomas. Previously, an antibody designated monoclonal antibody K1 was described which reacts with an antigen found on OVCAR-3 cells (from a human